MIM
AMED

MetLife Investment Management’s Amedisys AMED Stock Holding History

MetLife Investment Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,174
Closed -$1.68M – 2774
2025
Q1 		$1.68M Sell
18,174
-275
-1% -$25.4K 0.01% 1122
2024
Q4 		$1.67M Buy
18,449
+1,593
+9% +$146K 0.01% 1139
2024
Q3 		$1.63M Sell
16,856
-317
-2% -$30.9K 0.01% 1135
2024
Q2 		$1.58M Sell
17,173
-742
-4% -$68.8K 0.01% 1086
2024
Q1 		$1.65M Sell
17,915
-474
-3% -$44.4K 0.01% 1047
2023
Q4 		$1.75M Sell
18,389
-300
-2% -$28K 0.01% 1002
2023
Q3 		$1.75M Sell
18,689
-827
-4% -$76.4K 0.01% 962
2023
Q2 		$1.78M Sell
19,516
-397
-2% -$32.6K 0.01% 975
2023
Q1 		$1.46M Sell
19,913
-533
-3% -$46.1K 0.01% 1038
2022
Q4 		$1.71M Sell
20,446
-380
-2% -$34.3K 0.01% 975
2022
Q3 		$2.02M Sell
20,826
-344
-2% -$41K 0.02% 873
2022
Q2 		$2.23M Sell
21,170
-1,171
-5% -$150K 0.02% 859
2022
Q1 		$3.85M Buy
22,341
+6,542
+41% +$977K 0.02% 688
2021
Q4 		$2.56M Buy
15,799
+122
+0.8% +$19.6K 0.02% 766
2021
Q3 		$2.34M Sell
15,677
-599
-4% -$125K 0.02% 785
2021
Q2 		$3.99M Sell
16,276
-692
-4% -$182K 0.04% 512
2021
Q1 		$4.49M Sell
16,968
-987
-5% -$278K 0.04% 447
2020
Q4 		$5.27M Sell
17,955
-634
-3% -$163K 0.05% 339
2020
Q3 		$4.39M Sell
18,589
-640
-3% -$146K 0.05% 357
2020
Q2 		$3.82M Sell
19,229
-12,369
-39% -$2.31M 0.04% 404
2020
Q1 		$5.8M Sell
31,598
-334
-1% -$59.4K 0.08% 208
2019
Q4 		$5.33M Sell
31,932
-803
-2% -$119K 0.06% 320
2019
Q3 		$4.29M Buy
32,735
+1,437
+5% +$187K 0.05% 399
2019
Q2 		$3.8M Buy
31,298
+1,772
+6% +$210K 0.04% 488
2019
Q1 		$3.64M Buy
29,526
+17,717
+150% +$2.22M 0.04% 509
2018
Q4 		$1.38M Hold
11,809
– – 0.02% 910
2018
Q3 		$1.48M Sell
11,809
-2,163
-15% -$239K 0.02% 978
2018
Q2 		$1.19M Hold
13,972
– – 0.01% 954
2018
Q1 		$843K Hold
13,972
– – 0.01% 1081
2017
Q4 		$736K Buy
+13,972
New +$736K 0.01% 1177

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

MetLife Investment Management's AMED Position: Q2 2025 in Review

MetLife Investment Management sold out of Amedisys (AMED) in Q2 2025, closing a stake of 18,174 shares — an estimated $1.68M sold.

MetLife Investment Management first reported a position in AMED in Q4 2017 and held it in 30 quarters. The position peaked at $5.8M in Q1 2020. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

  • MetLife Investment Management reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 18,174 Amedisys shares in Q2 2025, an estimated $1.68M.
  • MetLife Investment Management first reported a position in Amedisys in Q4 2017 and held it in 30 quarters.
  • MetLife Investment Management's Amedisys position peaked at $5.8M in Q1 2020.
  • 319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.